Profound Medical Corp.
NASDAQ:PROFMedical - Devices
+$0.27 today
- Market cap
- $253.09M
- Beta
- 0.52
- P/E (TTM)
- -6.3
- EPS (TTM)
- -$1.07
Volume 0.08M
Average 0.12M
PROF Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Profound Medical Corp.NASDAQ: PROF
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $6.5M fell 20.6% year over year, ahead of the -29.9% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 9.7% from the prior quarter. Over 3 fiscal years it compounded at +22.1% a year.
Context
- Selling, general & admin amounted to 199.1% of revenue in FY2025, down 17.5 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 3 analysts of $61.84M (+89.6%) for the fiscal year ending Dec 2026, a step up from the +48.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $6.5M-9.7% QoQ
- Last fiscal yearDec 2025
- $32.61M+48.1% YoY
- LTMMar 2026
- $30.61M-29.9% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 32.61M USD
- Year-over-year change
- +48.1%
- 4-year CAGR
- +16.1%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 32.61M | +48.1% |
| FY2024 | 2024-12-31 | 22.02M | +18.3% |
| FY2023 | 2023-12-31 | 18.62M | +3.8% |
| FY2022 | 2022-12-31 | 17.93M | -0.2% |
| FY2021 | 2021-12-31 | 17.97M | — |
Selling, General & Admin vs competitors
How PROF compares with its peers on the latest reported figures
- PROF's LTM Mar 2026 selling, general & admin of $30.61M is the 7th highest of the 11 companies compared; the peer median is $39.36M.
- Its year-over-year change of -29.9% is the lowest of 11, against a peer median of +10.0%.
- Selling, general & admin amounts to 162.2% of revenue for PROF, versus a peer median of 122.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $95.81M | +14.8% | +8.8% | 63.2% | |
| LTM Mar 2026 | $95.47M | +58.4% | +7.6% | 83.9% | |
| LTM Mar 2026 | $51.33M | +16.1% | +25.8% | 114.4% | |
| LTM Mar 2026 | $50.4M | -0.9% | -15.8% | 47.1% | |
| LTM Mar 2026 | $42.18M | -24.8% | +1.9% | 130.7% | |
| LTM Mar 2026 | $36.54M | +18.5% | +18.5% | 63.3% | |
| LTM Mar 2026 | $30.61M | -29.9% | +22.1% | 162.2% | |
| LTM Mar 2026 | $29.38M | +2.8% | +28.6% | 4753.4% | |
| LTM Dec 2025 | $27.1M | +5.2% | -15.9% | 208.1% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $15.75M | +155.8% | +17.1% | 850.8% |
| LTM Mar 2026 | $12.62M | -4.8% | +18.6% | 426.6% | |
| Peer median (excluding PROF) | $39.36M | +10.0% | +13.0% | 122.5% | |
Competitors are the stored peer set for PROF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.87M | 6.68M | 7.2M | 10.17M | 16.38M |
| Cost of Revenue | 3.92M | 3.66M | 2.82M | 3.47M | 4.79M |
| Gross Profit | 2.95M | 3.02M | 4.38M | 6.7M | 11.59M |
| Gross Margin | 43.0% | 45.2% | 60.9% | 65.9% | 70.8% |
| Research & Development | 15.28M | 14.69M | 14.38M | 16.15M | 20.96M |
| Selling, General & Admin | 17.97M | 17.93M | 18.62M | 22.02M | 32.61M |
| Operating Expenses | 33.24M | 35.15M | 33M | 38.17M | 53.57M |
| Depreciation & Amortization | 1.88M | 1.6M | 1.15M | 891.06K | 569.8K |
| EBITDA | (28.65M) | (26.6M) | (26.78M) | (25.59M) | (41.41M) |
| EBITDA Margin | -416.8% | -398.2% | -372.0% | -251.7% | -252.8% |
| Operating Income | (30.29M) | (32.13M) | (28.62M) | (31.47M) | (41.98M) |
| Operating Margin | -440.7% | -480.9% | -397.5% | -309.6% | -256.3% |
| Interest Income | 203.2K | 1.05M | 1.64M | 1.37M | 1.09M |
| Interest Expense | 66.41K | 167.11K | 770K | 0 | 0 |
| Other Income / Expenses | (303K) | 3.74M | (81K) | 4.99M | (1.08M) |
| Income Before Tax | (30.59M) | (28.38M) | (28.7M) | (26.48M) | (43.06M) |
| Pre-Tax Margin | -445.1% | -424.8% | -398.6% | -260.5% | -262.9% |
| Income Tax Expense | 105K | 287K | (128K) | (1.9K) | 256.41K |
| Net Income | (30.7M) | (28.67M) | (28.57M) | (26.48M) | (43.32M) |
| Net Margin | -446.7% | -429.1% | -396.8% | -260.4% | -264.4% |
| EPS (Basic) | (1.50) | (1.38) | (1.35) | (1.07) | (1.43) |
| EPS (Diluted) | (1.50) | (1.38) | (1.35) | (1.07) | (1.43) |
| Weighted Avg Shares | 20.46M | 20.83M | 21.18M | 24.77M | 30.23M |
| Weighted Avg Shares (Diluted) | 20.47M | 20.83M | 21.18M | 24.77M | 30.23M |
Profound Medical Corp.
NASDAQ:PROF
Intrinsic Alpha fair value
Locked
Current Price
$6.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.